Progesterone Management Before Total Knee Arthroplasty
Systemic progesterone therapy (estrogen-containing hormone replacement therapy) should be discontinued 4 to 6 weeks before total knee arthroplasty to minimize venous thromboembolism risk.
Evidence-Based Recommendation
The FDA drug label for progesterone-containing hormone therapy explicitly states: "If feasible, estrogens with progestins should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization" 1. This guidance is based on data from the Women's Health Initiative showing a statistically significant 2-fold greater rate of venous thromboembolism (VTE) in women receiving combined estrogen-progestin therapy (35 versus 17 per 10,000 women-years), with increased risk for both deep vein thrombosis and pulmonary embolism 1.
Clinical Context and Nuances
Total knee arthroplasty is classified as high-bleeding-risk surgery with significant VTE risk, making the 4-6 week discontinuation period particularly relevant. The FDA label specifically addresses "surgery of the type associated with an increased risk of thromboembolism," which clearly encompasses major orthopedic procedures like TKA.
Important distinction: This recommendation applies specifically to estrogen-containing hormone therapy (combined estrogen-progestin formulations). The evidence for progesterone-only therapy is less clear, with recent systematic reviews suggesting that non-estrogen-containing transdermal hormone therapy may not require withholding 2. However, given the lack of definitive evidence and the elective nature of TKA, a cautious approach favoring discontinuation is warranted.
Practical Implementation
- Timing: Stop hormone therapy 4-6 weeks preoperatively
- Alternative contraception: Provide non-hormonal contraceptive options during the discontinuation period (a commonly overlooked step) 3
- Resumption: Can restart therapy postoperatively once the patient is fully mobile and VTE risk has normalized (typically 2-4 weeks post-surgery)
- VTE prophylaxis: Standard perioperative thromboprophylaxis protocols should still be followed regardless of hormone therapy status
Common Pitfalls
The available perioperative antithrombotic guidelines [4-4] focus primarily on anticoagulants and antiplatelet agents but do not specifically address hormone replacement therapy, creating a knowledge gap that clinicians must bridge using FDA drug labeling and clinical judgment. Do not assume that absence of specific guideline recommendations means hormone therapy can be continued—the FDA label provides clear direction.
Recent evidence suggests outcomes may be better than historically feared 5, but this emerging data is not yet sufficient to override established FDA guidance for major orthopedic surgery.